About Phathom Pharmaceuticals Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.phathompharma.com/
Frequently Asked Questions
What is the 52-week range for PHAT?
The 52-week high is $18.31 and the 52-week low is $6.91.
What is the P/E ratio for PHAT?
The P/E ratio data is currently unavailable.
What is the dividend yield for PHAT?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -232.78%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -41.34%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 8.32.
Analyst Recommendation Trends
Wall Street analyst consensus for PHAT over the last few months:
Latest PHAT News
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 dataTopline results expected in the first quarter of 2028pHalcon-NERD-302, if successful, is intended to support a potential VOQUEZNA label expansion to include as-needed treatment of heartburn episodes in patients with Non-Erosive GERD, a treatment regimen of interest to patients for which proton pump inhibitors (PPIs) a
Phathom Pharmaceuticals Initiates Registrational Phase 3 Study Of VOQUEZNA For As-Needed Treatment Of Non-Erosive GERD
Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results expected in the first
PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival
Leerink said that VOQUEZNA competes in a “highly genericized” gastroesophageal reflux disease market against long-available proton pump inhibitors (PPI).
Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case
Phathom Pharmaceuticals is targeting gastroenterologists to drive VOQUEZNA adoption and move toward sustainable profitability. Read more on PHAT stock here.
Leerink Partners Initiates Coverage On Phathom Pharmaceuticals with Market Perform Rating, Announces Price Target of $10
Leerink Partners analyst Daniel Clark initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Market Perform rating and announces Price Target of $10.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-03 | Breedlove Robert Charles | -460 | $9.05 | $4,163 |
| 2026-07-14 | Breedlove Robert Charles | -1,555 | $11.035 | $17,159 |
| 2026-05-22 | Parikh Asit | +28,000 | - | - |
| 2026-05-22 | Parikh Asit | -28,000 | - | - |
| 2026-05-20 | Parikh Asit | -17,500 | - | - |
| 2026-05-20 | Parikh Asit | +17,500 | $4.95 | $86,625 |
| 2026-05-19 | Parikh Asit | +24,122 | - | - |
| 2026-05-19 | Stenhouse Mark | +24,122 | - | - |
| 2026-05-19 | Schroeder Theodore R | +24,122 | - | - |
| 2026-05-19 | Topper James N | +24,122 | - | - |
| 2026-05-19 | KARBE FRANK | +24,122 | - | - |
| 2026-05-19 | COLA MICHAEL F | +24,122 | - | - |
| 2026-05-19 | FIELDS HEIDI | +24,122 | - | - |
| 2026-03-10 | Parikh Asit | +40,000 | - | - |
| 2026-03-10 | Parikh Asit | -40,000 | - | - |
| 2026-02-27 | Breedlove Robert Charles | -414 | $12.56 | $5,200 |
| 2026-02-27 | Breedlove Robert Charles | -964 | $12.56 | $12,108 |
| 2026-02-27 | Breedlove Robert Charles | +2,790 | - | - |
| 2026-02-27 | Breedlove Robert Charles | +13,000 | - | - |
| 2026-02-10 | Basta Steven L | -6,277 | $12.82 | $80,471 |
| 2026-02-10 | Basta Steven L | +12,362 | - | - |
| 2026-02-10 | Cook Anne Marie | -1,535 | $12.82 | $19,679 |
| 2026-02-10 | Cook Anne Marie | +3,461 | - | - |
| 2026-01-23 | Parikh Asit | +80,500 | - | - |
| 2026-01-23 | Parikh Asit | -80,500 | - | - |
| 2026-01-21 | Breedlove Robert Charles | -776 | $13.61 | $10,561 |
| 2026-01-13 | Parikh Asit | -8,750 | - | - |
| 2026-01-13 | Parikh Asit | +8,750 | $10.3 | $90,125 |
| 2026-01-02 | Narula Sanjeev | +42,848 | - | - |
| 2026-01-02 | Narula Sanjeev | +82,715 | - | - |
| 2026-01-02 | Basta Steven L | +226,156 | - | - |
| 2026-01-02 | Basta Steven L | +251,034 | - | - |
| 2026-01-02 | Cook Anne Marie | +67,878 | - | - |
| 2026-01-02 | Cook Anne Marie | +75,345 | - | - |
| 2025-12-19 | Parikh Asit | -8,750 | - | - |
| 2025-12-19 | Parikh Asit | +8,750 | $10.3 | $90,125 |
| 2025-12-18 | Breedlove Robert Charles | -230 | $16.28 | $3,744 |
| 2025-12-17 | Basta Steven L | -31,502 | $15.36 | $483,871 |
| 2025-12-17 | Basta Steven L | +62,038 | - | - |
| 2025-12-17 | Cook Anne Marie | -7,703 | $15.36 | $118,318 |
| 2025-12-17 | Cook Anne Marie | +17,370 | - | - |
| 2025-11-28 | Basta Steven L | -90,000 | - | - |
| 2025-11-28 | Basta Steven L | -48,375 | $15.62 | $755,618 |
| 2025-11-28 | Basta Steven L | +90,000 | - | - |
| 2025-11-03 | Breedlove Robert Charles | -524 | $13.51 | $7,079 |
| 2025-10-06 | Narula Sanjeev | +144,000 | - | - |
| 2025-10-06 | Narula Sanjeev | +200,000 | - | - |